预约演示
更新于：2026-06-20
Perindopril/Indapamide
培哚普利吲达帕胺
更新于：2026-06-20
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS号182176-83-6 |
关联
14
项与 培哚普利吲达帕胺 相关的临床试验CTR20250879
培哚普利吲达帕胺片在健康研究参与者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性试验
CTR20250386
随机、开放、单剂量、两制剂、两序列、交叉对照设计，评价空腹及餐后状态下单次口服受试制剂培哚普利吲达帕胺片与参比制剂培哚普利吲达帕胺片（商品名：百普乐®）在中国健康受试者中的生物等效性正式试验
CTR20231821
培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
100 项与 培哚普利吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的专利（医药）
登录后查看更多信息
157
项与 培哚普利吲达帕胺 相关的文献（医药）2026-05-01DIABETES OBESITY & METABOLISM
Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the
ADVANCE
Study
Article
作者: Zhang, Yonghong ; Gao, Yijie ; Chen, Xiaoying ; Mancia, Giuseppe ; Marre, Michel ; Harrap, Stephen ; Woodward, Mark ; Wang, Ruirui ; Anderson, Craig S. ; Peters, Ruth ; Hamet, Pavel ; Harris, Katie ; Chalmers, John ; Chen, Linan
ABSTRACT:
Aims:
To determine the association of insulin resistance, assessed using the estimated glucose disposal rate (eGDR), and the risk of adverse clinical outcomes, and determine any effect modification on the efficacy of glucose‐ and blood pressure (BP)‐lowering treatments.
Materials and Methods:
Briefly, 11 140 participants with type 2 diabetes (T2D) were recruited from 20 countries for the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial. eGDR was derived from waist circumference, hypertension status and glycated haemoglobin, calculated in 11 081 participants. Multivariable Cox models were used to estimate hazard ratios (HRs) of the association of eGDR with clinical events.
Results:
Over a median of 5 years of follow‐up, 2117 participants (19.1%) experienced a major macrovascular or microvascular event. Compared with individuals in the lowest quarter of eGDR, those in the highest quarter had significantly lower risks of a composite major macrovascular and microvascular event (HR 0.72, 95% CI 0.62–0.84). Similar associations were seen for major macrovascular events (HR 0.68, 95% CI 0.55–0.85), major microvascular events (HR 0.78, 95% CI 0.63–0.96), all‐cause mortality (HR 0.69, 95% CI 0.55–0.86), and cardiovascular mortality (HR 0.62, 95% CI 0.45–0.85). No significant effect modification was observed across eGDR quarters for the efficacy or safety of intensive glucose control (vs. standard control) or BP–lowering treatment (vs. placebo).
Conclusion:
These findings highlight the value of eGDR as a prognostic marker for T2D. Intensive glucose‐ and BP‐lowering treatments remain beneficial regardless of insulin resistance status.Trial Registration:ClinicalTrials.gov
identifier: NCT00145925
2026-04-07Journal of the American Heart Association
Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial
Article
作者: Shajahan, Sultana ; MacMahon, Stephen ; Mancia, Giuseppe ; Anderson, Craig S ; Peters, Ruth ; Harris, Katie ; Woodward, Mark ; Harrap, Stephen ; Chalmers, John ; Wang, Nelson ; Tully, Phillip J ; Carcel, Cheryl ; Poulter, Neil
Background:
Blood pressure (BP) variability and cumulative BP load are significantly associated with cardiovascular disease risk beyond mean systolic BP, but less is known regarding their associations with cognitive decline/dementia and whether these associations differ by cognitive function at baseline or by sex. The aims of this study were to determine associations of different BP parameters with cognitive decline/dementia in patients with type 2 diabetes and explore differences by mild cognitive impairment at baseline and sex.
Methods:
Using data from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) study, BP parameters were calculated from an 18‐month exposure window comprising measurements at 3, 4, 6, 12, and 18 months, after randomization. Logistic regression was used to estimate the odds ratio (OR) per SD higher and 95% CI for the associations of BP parameters with the composite outcome of cognitive decline (≥3 points from baseline on the Mini‐Mental State Examination) or clinical diagnosis of dementia.
Results:
Of the 11 140 ADVANCE participants, 9586 patients had 5 complete BP measurements within the 18‐month exposure window. After a mean follow‐up of 3.5 years, 1674 (17.5%) participants were diagnosed with cognitive decline and/or dementia. Overall, variability and baseline pulse pressure (PP), but not BP load, were associated with higher odds of cognitive decline/dementia (OR: variability in systolic BP, 1.11 [95% CI, 1.05–1.17]; diastolic BP, 1.11 [95% CI, 1.05–1.17]; PP, 1.05 [95% CI, 1.00–1.11]; mean arterial pressure, 1.13 [95% CI, 1.07–1.19]; and baseline PP, 1.19 [95% CI, 1.13–1.25]). There were no differences by mild cognitive impairment at baseline or sex.
Conclusions:
Higher BP variability and baseline PP, but not mean BP or BP load, were associated with higher odds of cognitive decline/dementia in patients with type 2 diabetes. BP variability and PP may be important therapeutic markers for the preservation of brain health.
Registration:
URL:
https://clinicaltrials.gov
; Unique Identifier: NCT00145925.
2025-05-01BMJ Open Diabetes Research & Care
Relationship between time-varying achieved HbA1c and risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study
Article
作者: Woodward, Mark ; Mancia, Giuseppe ; Marre, Michel ; Sapp, John ; Carew, Allie S ; Samuel, Michelle ; Harris, Katie ; Warren, Rachel A ; Selvin, Elizabeth ; Chalmers, John ; Lavallée, Samantha K ; Rimm, Eric ; Levy, Andrew P ; Harrap, Stephen ; Cahill, Leah E ; Poulter, Neil
Introduction:
This study sought to determine whether the association between attaining specific glycated hemoglobin (HbA1c) targets (<7.0% (<53 mmol/mol) and ≥8.0% (≥64 mmol/mol) compared with 7.0%–7.9%) over time and risk of incident coronary artery disease (CAD) was dependent on haptoglobin (Hp) phenotype in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study.
Research design and methods:
Prospectively collected HbA1c data from the ADVANCE biomarker case-cohort study, updated at 6 months and every 12 months thereafter over a median of 5.0 (IQR 4.5–5.3) years, were analyzed in relation to incident CAD in the Hp2-2 (n=1323) and non-Hp2-2 (n=2069) phenotypes separately using weighted multivariable-adjusted Cox regression models. Additional a priori stratifications by sex, race, previous cardiovascular disease (CVD), and type 2 diabetes duration were performed.
Results:
Mean HbA1c was similar in each phenotype group throughout the study. Compared with HbA1c of 7.0%–7.9%, HbA1c <7.0% was not associated with CAD risk for any phenotype group or subgroup. HbA1c ≥8.0% compared with 7.0%–7.9% over time was associated with higher CAD risk for the Hp2-2 phenotype only (HR 1.53, 95% CI 1.01 to 2.32; no significant association in the non-Hp2-2 type: 1.26, 0.89 to 1.77, p-interaction=0.71); this was pronounced when those with previous CVD at baseline were excluded (Hp2-2: 2.80, 1.41 to 5.53, p-interaction=0.03). Compared with HbA1c of <8.0%, having HbA1c ≥8.0% was associated with a 59% higher CAD risk among participants with the Hp2-2 phenotype (1.59, 1.12 to 2.26) and a 39% higher CAD risk among participants without the Hp2-2 phenotype (1.39, 1.03 to 1.88, p-interaction=0.97).
Conclusions:
The present ADVANCE analysis suggests that not having HbA1c ≥8.0%, rather than achieving HbA1c <7.0%, was found to be particularly important for CAD prevention among people with type 2 diabetes and the common Hp2-2 phenotype. While the subgroup analyses were likely underpowered, their inclusion is hypothesis generating and can be used in future meta-analyses to improve power and generalizability.
100 项与 培哚普利吲达帕胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2005-09-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床3期 | 中国 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 加拿大 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 荷兰 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 英国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 中国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 荷兰 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 英国 | 2001-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Active BP lowering treatment (combination perindopril±indapamide) | 簾鏇築願構網顧鹽積夢(獵鹹製鹹積簾糧憲壓獵) = 衊艱淵鹹選觸選淵鹽蓋 顧糧鹽構鑰壓築膚鬱膚 (觸夢製築製夢積餘鬱壓 ) | - | 2023-03-01 | ||
Placebo | 簾鏇築願構網顧鹽積夢(獵鹹製鹹積簾糧憲壓獵) = 憲齋淵積構餘鑰糧餘構 顧糧鹽構鑰壓築膚鬱膚 (觸夢製築製夢積餘鬱壓 ) | ||||||
临床3期 | 9,694 | 鑰蓋積廠鏇憲獵淵鬱醖(餘選鬱夢餘觸遞築網鏇): 0.91 (95% CI, 0.83 ~ 1.0), P-Value = 0.04 | - | 2022-08-01 | |||
Placebo | |||||||
临床3期 | 682 | (Intensive blood glucose control) | 憲窪淵蓋廠鬱鹹蓋網鬱(糧襯鏇鏇簾淵鑰構觸網) = 繭願簾鹽壓醖夢鹹夢鑰 膚範簾鏇遞範鹹製衊壓 (衊衊襯願築觸窪獵繭願, -20.2%, ~ 0.9%) 更多 | - | 2022-04-16 | ||
(Intensive blood pressure control) | 憲鑰廠積鹹夢構網艱齋(鹽壓觸構襯鏇築顧製願) = 糧鏇衊衊鏇鑰壓繭廠範 顧襯窪鏇鬱壓淵憲鏇鏇 (獵餘齋鬱獵襯築廠夢築, -8.9 ~ 3.6) | ||||||
临床3期 | 11,140 | 憲窪積選齋憲鑰鏇膚壓(鏇構夢積構遞鹽鏇鏇糧) = 糧淵衊鹹積繭鬱壓觸網 繭鏇遞簾積艱壓壓壓鏇 (積醖遞顧廠蓋糧廠鏇範, 6.15 ~ 10.63) | - | 2021-05-25 | |||
临床3期 | 11,140 | 製願鬱簾膚糧築窪夢糧(網構構構鬱鑰選膚膚鬱): 0.78 (95% CI, 0.71 ~ 0.86) | - | 2021-04-20 | |||
Placebo | |||||||
临床3期 | 9,195 | (³30% decrease in UACR) | 遞鹽衊餘鹽膚憲築願積(繭醖襯簾糧齋廠齋願憲): HR = 0.1 (95% CI, 0.01 ~ 0.79) | 积极 | 2015-11-03 | ||
(<30% decrease to <30% increase in UACR) | |||||||
N/A | - | 鬱憲鹹範淵淵願蓋襯鑰(鏇糧構築遞艱窪顧鏇艱): 0.91 (95% CI, 0.84 ~ 0.99), P-Value = 0.03 | - | 2014-10-09 | |||
Placebo | |||||||
临床3期 | - | 鏇築糧獵繭鬱鏇齋獵繭(膚醖製繭窪構憲鹽襯製) = 遞膚鹽構構製鹽齋獵窪 願衊醖蓋觸醖鑰鬱網獵 (顧築網衊製鏇衊積範鬱, 12 ~ 50) | - | 2009-11-01 | |||
願築壓鑰構齋鏇膚選淵(鹹醖構簾窪醖簾鑰鏇製) = 鏇築鹹積夢鹹網壓鹽繭 窪鬱憲鹹餘壓遞夢築鬱 (構鹹遞膚繭鑰築糧襯鑰, 1 ~ 32) 更多 | |||||||
临床3期 | 11,140 | (Normal cognitive function) | 積壓鏇繭蓋遞鬱網繭艱(鹽艱憲觸艱齋壓觸築壓): HR = 1.33 (95% CI, 1.16 ~ 1.54), P-Value = < 0.03 更多 | - | 2009-11-01 | ||
(Mild cognitive dysfunction) | |||||||
临床3期 | 11,140 | 願獵窪顧鹽醖窪範願衊(鏇膚膚鑰壓窪鏇遞艱觸) = 網積廠觸選壓窪積鹽夢 餘獵網鹹糧壓壓窪獵鑰 (範積廠顧壓艱觸範糧製 ) | - | 2007-09-08 | |||
Placebo | 願獵窪顧鹽醖窪範願衊(鏇膚膚鑰壓窪鏇遞艱觸) = 襯鏇網廠壓餘淵鏇艱鏇 餘獵網鹹糧壓壓窪獵鑰 (範積廠顧壓艱觸範糧製 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用